NRC
National Research Corporation18.43
+0.43+2.39%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
425.06MP/E (TTM)
25.96Basic EPS (TTM)
0.71Dividend Yield
0.03%Recent Filings
10-K
FY2025 results
NRC Health's FY2025 revenue fell 4% y/y to $137M amid existing customer churn, yet Q4 signaled turnaround with TRCV surging 8% y/y to $144M—hitting a record $152M by early 2026 on new sales and retention gains. Operating margin contracted to 16% from 25%, hit by $6.6M executive transition bonuses and $3.3M stock comp, while direct expenses dropped 8% via automation. Q4 momentum shone through efficiency gains and TRCV acceleration. Debt stood at $79M on the Delayed Draw Term Loan (6.22%); $30M revolver available. Q4 dividends rose to 16¢/share. TRCV points to 2026 growth. Healthcare consolidation threatens budgets.
8-K
TRCV hits $152M record
National Research Corporation hit an all-time high Total Recurring Contract Value of $152 million as of March 4, 2026, up 6% from end-2025 and 13% year-over-year. TRCV signals revenue from renewable contracts over the next 12 months. CEO Trent Green credits partner confidence. This excludes Q1 2026 full results.
8-K
Q4 revenue dips, TRCV jumps 8%
NRC Health reported Q4 2025 revenue of $35.2 million, down from $36.9 million a year ago, yet TRCV surged 8% to $144.1 million. GAAP net income hit $1.8 million; Adjusted EBITDA reached $8.7 million at 25% of revenue. Cash flow strengthened 13% to $7.2 million. Board declared $0.16 quarterly dividend, payable April 10.
10-Q
Q3 FY2025 results
NRC Health posted Q3 revenue of $34.6M, down 3% y/y yet holding operating income steady at $7.7M with margins firm at 22% as direct expenses plunged 19% from lower conferences and workforce cuts. Operating income dipped to $17.9M YTD (down 30% y/y) on SG&A jumps from executive comp, while diluted EPS fell to $0.18 from $0.24 (reconciles to 22.1M shares; anti-dilution from 553k options). Cash fell to $2.2M amid $19.3M operating cash flow, $9.6M capex, $20.2M buybacks, and $8.3M dividends, but $80.4M Delayed Draw Term Loan (6.63%, due 2030) leaves $30M revolver and $27.6M term availability intact; covenants met. New CFO joined September 29. Client non-renewals pressure growth.
8-K
Q3 TRCV up 8%, cash flow soars
NRC Health reported Q3 revenue of $34.6 million, down from $35.8 million last year, yet TRCV surged 8% to $141.7 million on strong sales and retention. Cash flow from operations jumped 46% to $13.8 million. Adjusted EBITDA hit $10.9 million, up 11%. Board hiked quarterly dividend 33% to $0.16 per share.
IPO
Website
Employees
Sector
Industry
CNXC
Concentrix Corporation
39.45+0.67
DH
Definitive Healthcare Corp.
2.29-0.01
FORA
Forian Inc.
2.14+0.00
HCAT
Health Catalyst, Inc
2.44+0.09
HSTM
HealthStream, Inc.
23.91-0.47
LNC
Lincoln National Corporation
45.30+0.10
NHC
National HealthCare Corporation
138.93-0.94
NUTX
Nutex Health Inc.
171.72-4.06
SYRA
Syra Health Corp.
0.07+0.01
WORX
SCWorx Corp.
0.21-0.01